Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 507-514

  Lodise, Thomas P ^a,b   Patel, Nimish ^a   Lomaestro, Ben M ^c   Rodvold, Keith A ^d   Drusano, George L ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; BAYES THEOREM; BLOODSTREAM INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ARTICLE; COMORBIDITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; GRAM POSITIVE INFECTION; HOSPITAL PATIENT; HUMAN; MALE; NEPHROTOXICITY; NEUTROPHIL COUNT; OSTEOMYELITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; STEADY STATE; TIME; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CREATININE; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INPATIENTS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; NEW YORK; PLASMA; RETROSPECTIVE STUDIES; TIME FACTORS; VANCOMYCIN;

EID: 67651113645     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600884     Document Type: Article

References (38)

1. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High- dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
2. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-15.
3. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Che- mother 2008;62:168-71.
4. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6.
5. D'Argenio DZ, Schumitzky A. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual, Bio- medical Simulations Resource, University of Southern California, Los Angeles, California, 1997. Available at: http://bmsr.usc.edu/Software/ ADAPT/ADAPT.html. Accessed 10 October 2008.
6. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat Rev Microbiol 2004; 2:289-300.
7. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics: insights from the SocietyofInfectious Diseases Pharmacists. Pharmacotherapy 2006;26:1320-32.
8. Guidelines for the management of adults with hospital-acquired, ven-tilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
9. Zhang H, Burthon S. Recursive partitioning in the health sciences. New York: Springer, 1999.
10. Drusano GL, Ambrose PG, Bhavnani SM, et al. Vancomycin dose recommendations for hospital-, ventilator- or health care-associated pneumonia and the attainment of vancomycin trough concentrationsof 15-20 mg/L: cognitive dissonance. In: Programs and abstracts of the 45th Annual Meeting of the Infectious Diseases Society of America (San Diego, CA). Alexandria, VA: Infectious Diseases Society ofAmerica, 2007.
11. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32:848-52.
12. Rodvold KA, Pryka RD, Garrison M, Rotschafer JC. Evaluation of a two-compartment Bayesian forecasting program for predicting van- comycin concentrations. Ther Drug Monit 1989; 11:269-75.
13. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
15. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006;42(Suppl 1):S3-4.
16. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42(Suppl 1):S35-9.
17. Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42(Suppl 1): S5-12.
18. Aronoff GR, Sloan RS, Dinwiddie CB Jr, Glant MD, Fineberg NS, LuftFC. Effects of vancomycin on renal function in rats. Antimicrob Agents Chemother 1981; 19:306-8.
19. Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998; 83:2597-607.
20. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
21. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83:1091- 7.
22. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Van-comycin pharmacokinetics in burn patients and intravenous drug abus- ers. Antimicrob Agents Chemother 1990; 34:792-5.
23. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149:1777-81.
24. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-43.
25. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993; 27:594-8.
26. Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18:544-6.
27. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
28. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus van- comycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-93.
29. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double- blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46:647-55.
30. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus stan-ard therapy for bacteremia and endocarditis caused byStaphylococcus aureus. N Engl J Med 2006; 355:653-65.
31. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gen- tamicin for Staphyloccus aureus bacteremia and endocarditis is neph- rotoxic. Clin Infect Dis 2009;48:713-21.
32. King DW, Smith MA. Proliferative responses observed following van- comycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro 2004; 18:797-803.
33. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 2005; 97:325-32.
34. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 2005; 215:227-33.
35. Cetin H, Olgar S, Oktem F, et al. Novel evidence suggesting an anti- oxidant property for erythropoietin on vancomycin-induced nephro- toxicity in a rat model. Clin Exp Pharmacol Physiol 2007;34:1181-5.
36. Hodoshima N, Nakano Y, Izumi M, et al. Protective effect of inactive ingredients against nephrotoxicityofvancomycin hydrochloride inrats.Drug Metab Pharmacokinet 2004; 19:68-75.
37. Toyoguchi T, Takahashi S, Hosoya J, Nakagawa Y, Watanabe H. Ne- phrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother 1997; 41:1985-90.
38. Le Moyec L, Racine S, Le Toumelin P, et al. Aminoglycoside and gly- copeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Crit Care Med 2002;30: 1242-5.